{"id":"block_63b60dfe3e32c","name":"acf\/block-resource-summary","data":{"resource_summary_0_summary_heading":"Study Background","resource_summary_0_summary_rich_text_module_0_content":"IMpower is a phase 3 study measuring the effect of carboplatin and paclital (CP) combined with atezolizumbab (A) and or bevacizumab (B) in patients with advanced non-squamous NSCLC.\r\n\r\nThe study demonstrated efficacy of ABCP regardless of PD-L1 status. Though high PD-L1 expression and immune phenotype, assessed via RNA-seq, was associated with increased benefit.\r\n\r\nIncreased benefit based on immune phenotype points to the importance of understanding factors in the tumor micro-environment that are predictive of benefit from immuno-oncology (IO) and VEGF inhibition.","resource_summary_0_summary_rich_text_module_0_button":"","resource_summary_0_summary_rich_text_module":1,"resource_summary_0_summary_document_link":"https:\/\/pathaiwp.wpenginepowered.com\/wp-content\/uploads\/2023\/01\/Taylor-Weiner-et-al.-ASCO-2020-Poster-scaled.jpeg","resource_summary_0_summary_document_button_label":"View Poster","resource_summary_0_summary":"","resource_summary_0_author_heading":"Authors","resource_summary_0_author_rich_text_module_0_content":"Taylor-Weiner et al.","resource_summary_0_author_rich_text_module_0_button":"","resource_summary_0_author_rich_text_module":1,"resource_summary_0_author":"","resource_summary":1,"jump_link_label":""},"align":"","mode":"edit"}
Get In Touch
PathAI Media
Company Contact
Liz Storti
Chief People Officer
Media Contact
Daniel Donato
LifeSci Communications
516-474-0554